Oxford Nanopore shares slide to lowest since April 2025 after growth outlook cut By Investing.com
Oxford Nanopore Technologies shares fell more than 14% to the lowest since April 7, 2025, after the company cut its growth outlook. It expects six-month revenue of about £116.5m, up 11% reported, but said trading was below expectations. It cited weakness in China and disruption in the Middle East, plus order timing in the Americas.
How this was made
The 30-second read
Why it matters
The disclosed first-half revenue growth shortfall and narrowed underlying growth pace, attributed to China weakness and Middle East disruption plus Americas order timing, are likely to drive near-term estimate cuts and heightened sensitivity to interim commentary in August.
Market read
Traders should treat this as a guidance-quality event, not just a price move, because the article provides concrete revenue growth expectations and a revised underlying growth framework.
What to watch
Applied Markets growth was strong (about 22% overall, with clinical up ~35% and BioPharma up ~25%), suggesting the weakness may be concentrated in specific geographies or timing rather than broad product demand.
Background
Oxford Nanopore is a London-listed DNA sequencing company that provides guidance on constant-currency revenue growth and gross margin, with adjusted EBITDA breakeven targeted for FY27.
Ticker impact
Oxford Nanopore cut its underlying full-year growth pace after first-half revenue growth undershot expectations and guidance was narrowed.
Near-term pressure likely to persist until interim results in August clarify demand durability and the contribution from collaboration and licensing.
The article discloses specific revenue growth expectations for the six months ended June 30 and narrows the constant-currency growth outlook, which typically drives estimate revisions and multiple compression for growth stocks.
Market effects
Signals demand volatility for DNA sequencing tools, with China and Middle East disruptions potentially affecting read-across sentiment across genomics instrumentation.
Highlights China revenue decline and Middle East disruption as key swing factors, which can influence regional biotech equipment sentiment.
Reinforces that geopolitical and regional commercial execution can quickly translate into sequencing platform revenue timing and guidance changes.
Counterpoint
The company kept constant-currency full-year growth within a prior 21% to 25% range and expects additional collaboration and licensing revenue in the second half, which could offset near-term softness.
Key entities
- companyOxford Nanopore Technologies Plc
DNA-sequencing company whose first-half revenue growth undershot expectations and whose underlying full-year guidance pace was narrowed.
- personFrancis Van Parys
Chief Executive Officer who said the company remains on track for adjusted EBITDA breakeven during FY27.
